Abstract
In 55 patients in whom warfarin control had been satisfactory for at least 4 months, warfarin dose, plasma warfarin concentration and plasma clearance were measured. The mean dose to maintain the BCR (INR) between 2.3 and 3.3 was 5.1 +/- 2 mg day-1 (range 1.5-10 mg). Plasma warfarin concentrations and warfarin clearance were log-normally distributed with 95% confidence limits between 0.8 and 2.4 mg l-1 and 2.5 and 8.71 day-1 respectively. These confidence limits were used to construct algorithms which correctly predicted the cause of abnormal warfarin sensitivity in two patients and resistance in two further patients. These algorithms should help to identify the cause of abnormal warfarin responsiveness in the clinical setting.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andreasen P. B., Vesell E. S. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin Pharmacol Ther. 1974 Dec;16(6):1059–1065. doi: 10.1002/cpt19741661059. [DOI] [PubMed] [Google Scholar]
- Bjornsson T. D., Blaschke T. F., Meffin P. J. High-pressure liquid chromatographic analysis of drugs in biological fluids I. Warfarin. J Pharm Sci. 1977 Jan;66(1):142–144. doi: 10.1002/jps.2600660144. [DOI] [PubMed] [Google Scholar]
- Hotraphinyo K., Triggs E. J., Maybloom B., Maclaine-Cross A. Warfarin sodium: steady-state plasma levels and patient age. Clin Exp Pharmacol Physiol. 1978 Mar-Apr;5(2):143–149. doi: 10.1111/j.1440-1681.1978.tb00664.x. [DOI] [PubMed] [Google Scholar]
- O'REILLY R. A., AGGELER P. M., HOAG M. S., LEONG L. S., KROPATKIN M. L. HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED. N Engl J Med. 1964 Oct 15;271:809–815. doi: 10.1056/NEJM196410152711602. [DOI] [PubMed] [Google Scholar]
- Rees A., Dalal J. J., Reid P. G., Henderson A. H., Lewis M. J. Dangers of amiodarone and anticoagulant treatment. Br Med J (Clin Res Ed) 1981 May 30;282(6278):1756–1757. doi: 10.1136/bmj.282.6278.1756-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Robinson D. S., Benjamin D. M., McCormack J. J. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther. 1971 May-Jun;12(3):491–495. doi: 10.1002/cpt1971123491. [DOI] [PubMed] [Google Scholar]
- Routledge P. A., Chapman P. H., Davies D. M., Rawlins M. D. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol. 1979 Jun 12;15(5):319–322. doi: 10.1007/BF00558434. [DOI] [PubMed] [Google Scholar]
- Watt A. H., Stephens M. R., Buss D. C., Routledge P. A. Amiodarone reduces plasma warfarin clearance in man. Br J Clin Pharmacol. 1985 Dec;20(6):707–709. doi: 10.1111/j.1365-2125.1985.tb05135.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yacobi A., Udall J. A., Levy G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):552–558. doi: 10.1002/cpt1976195part1552. [DOI] [PubMed] [Google Scholar]